Elimination of alfentanil delivered by infusion is not altered by the chronic administration of atorvastatin

European Journal of Anaesthesiology

Volumn 20, Issue 8, 2003, Pages 662-667

  McDonnell, Conor G ^a   Malkan, D ^a   Van Pelt, F D ^b   Shorten, G D ^a  

^a University College Cork and INFANT Centre   (Ireland)

^b UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

Anaesthesia, intravenous; Analgesics, opioid, alfentanil; Chemical and pharmacological phenomena, drug interactions; Enzyme inhibitors, hydroxymethylglutaryl coa reductase inhibitors; Metabolism, area under the curve, biotransformation, pharmacokinetics

Indexed keywords

ALFENTANIL; ATORVASTATIN; CYTOCHROME P450 3A4; METOCLOPRAMIDE; MORPHINE; NITROUS OXIDE; PANCURONIUM; SEVOFLURANE; STATINE DERIVATIVE; TENOXICAM; THIOPENTAL;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARTMENT MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEVICE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INHIBITION; DRUG METABOLISM; ELECTIVE SURGERY; FEMALE; GAS CHROMATOGRAPHY; HUMAN; HYPERCHOLESTEROLEMIA; LONG TERM CARE; MALE;

ADULT; AGED; ALFENTANIL; ANALGESICS, OPIOID; ANTICHOLESTEREMIC AGENTS; AREA UNDER CURVE; CHROMATOGRAPHY, GAS; DRUG INTERACTIONS; FEMALE; HEPTANOIC ACIDS; HUMANS; HYPERCHOLESTEROLEMIA; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PYRROLES; TIME FACTORS;

EID: 0042065205     PISSN: 02650215     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0265021503001078     Document Type: Article

References (19)

1. Erikssen J, Madsen S. Treatment of hypercholesterolemia with statins. Tidsskr Nor Laegeforen 1997; 117: 3216-3220.
2. Prueksaritanont T, Gorham LM, Ma B, et al. In vitro metabolism of simvastatin in humans [SBT] identification of metabolizing enzymes and effect of the drug on hepatic P450s. Drug Metab Dispos 1997; 25: 1191-1199.
3. Chang GWM, Kam PCA. The physiological and pharmacological roles of cytochrome P450 isoenzymes. Anaesthesia 1999; 54: 42-50.
4. Nelson DR, Koymans L, Kamtaki T, et al. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 1996; 6: 1-42.
5. Segaert MF, De Soete C, Vandwiele I, Verbanck J. Drug interaction-induced rhabdomyolysis. Nephrol Dial Transplant 1996; 11: 1846-1847.
6. Guitton J, Buronfosse T, Desage M, et al. Possible involvement of multiple cytochrome P450s in fentanyl and sufentanil metabolism as opposed to alfentanil. Biochem Pharmacol 1997; 53: 1613-1619.
7. Labroo RB, Thummel KE, Kunze KL, Podoll T, Trager WF, Kharasch ED. Catalytic role of cytochrome P450 3A4 in multiple pathways of alfentanil metabolism. Drug Metab Dispos 1995; 23: 490-496.
8. Janicki PK, James MFM, Erskine WAR. Propofol inhibits enzymatic degradation of alfentanil and sufentanil by isolated liver microsomes in vitro. Br J Anaesth 1992; 68: 311-312.
9. Meistelman C, Saint-Maurice C, Lepaul M. A comparison of alfentanil pharmacokinetics in children and adults. Anesthesiology 1987; 66: 13-16.
10. Gibaldi M, Perrier D. Pharmacokinetics, 2nd edn. New York, USA: Marcel Dekker, 1982.
11. Kharasch ED, Russell M, Mautz D, et al. The role of cytochrome P450 3A4 in alfentanil clearance. Implications for interindividual variability in disposition and perioperative drug interactions. Anesthesiology 1997; 87: 36-50.
12. Meuldermans W, Van Peer A, Hendrickx J, et al. Alfentanil pharmacokinetics and metabolism in humans. Anesthesiology 1988; 69: 527-534.
13. Michniewicz BM, Black AE, Sinz MW, et al. In vitro and in vivo metabolism of atorvastatin (CI-981). ISSX Proc 1994; 6: 93.
14. Ishigami M, Hoda T, Takasaki W, et al. A comparison of the effects of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors on the CYP 3A4-dependent oxidation of mexazolam in vitro. Drug Metab Dispos 2001; 29: 282-288.
15. Bartkowski RR, Goldberg ME, Larijani GE, Boerner T. Inhibition of alfentanil metabolism by erythromycin. Clin Pharmacol Ther 1989; 46: 99-102.
16. Palkama VJ, Isohanni MH, Neuvonen PJ, Olkkola KT. The effect of intravenous and oral fluconazole on the pharmacokinetics and pharmacodynamics of intravenous alfentanil. Anesth Analg 1998; 87: 190-194.
17. Penon C, Negre I, Ecoffey C, Gross JB, Levron JC, Samii K. Analgesia and ventilatory response to carbon dioxide after intramuscular and epidural alfentanil. Anesth Analg 1988; 67: 313-317.
18. Maltz HC, Balog DL, Cheigh JS. Rhabdomyolysis associated with concomitant use of atorvastatin and cyclosporine. Ann Pharmacother 1999; 33: 1176-1179.
19. Norman DJ, Illingworth DR, Munson J, Hosenpud J. Myolysis and acute renal failure in a heart-transplant patient receiving lovastatin. N Engl J Med 1988; 318: 46-47.